FDA Extends PDUFA Date for Priority Review of NDA for Salix Pharma's (SLXP) Crofelemer Tablets

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the U.S. FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for the Agency’s Priority Review of the New Drug Application (NDA) for Crofelemer 125 mg tablets for the proposed indication for the control and symptomatic relief of diarrhea in patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) on anti-retroviral therapy (ART). The FDA has notified Salix that it requires additional time for a full review of the submission and has extended the June 5, 2012 goal date by three months. The extended user fee goal date is September 5, 2012. The FDA did not request additional studies.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Elroy Air wins $46M U.S. Army contract for cargo drone system
• Kimbell Royalty closes $221.2M mineral rights acquisition